Benefits of topical estrogen in the treatment of urogenital menopause syndrome

Reference

• 1. Katzenellenbogen B.S., Montano M.M., Ediger T.R. et al. (2000) Estrogen receptors: selective ligands, partners, and distinctive pharmacology. Recent Prog. Horm. Res., 55: 163–193.
• 2. Katzenellenbogen B.S., Choi I., Delage-Mourroux R. et al. (2000) Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology. J. Steroid Biochem. Mol. Biol., 74: 279–285.
• 3. Hall J.M., Couse J.F., Korach K.S. (2001) The multifaceted mechanisms of estradiol and estrogen receptor signaling. J. Biol. Chem., 276: 36869–36872.
• 4. Imamov O., Shim G.J., Warner M., Gustafsson J.A. (2005) Estrogen receptor beta in health and disease. Biol. Reprod., 73: 866–871.
• 5. Dahlman-Wright K., Cavailles V., Fuqua S.A. et al. (2006) International union of pharmacology. LXIV. Estrogen receptors. Pharmacol. Rev., 58: 773–781.
• 6. Planey S.L., Kumar R., Arnott J.A. (2014) Estrogen receptors (ERα versus ERβ): friends or foes in human biology? J. Recept. Signal. Transduct. Res., 34: 1–5.
• 7. Vrtačnik P., Ostanek B., Mencej-Bedrač S., Marc J. (2014) The many faces of estrogen signaling. Biochem. Med. (Zagreb), 24: 329–342.
• 8. Helsen C., Claessens F. (2014) Looking at nuclear receptors from a new angle. Mol. Cell Endocrinol., 382: 97–106.
• 9. Bondesson M., Hao R., Lin C.Y. et al. (2015) Estrogen receptor signaling during vertebrate development. Biochim. Biophys. Acta, 1849: 142–151.
• 10. Karas R.H., Patterson B.L., Mendelsohn M.E. (1994) Human vascular smooth muscle cells contain functional estrogen receptor. Circulation, 89: 1943–1950.
• 11. Miller V.M., Duckles S.P. (2008) Vascular actions of estrogens: functional implications. Pharmacol. Rev., 60: 210–241.
• 12. Clarkson T.B., Mehaffey M.H. (2009) Coronary heart disease of females: lessons learned from nonhuman primates. Am. J. Primatol., 71(9): 785–793.
• 13. Xing D., Nozell S., Chen Y.F. et al. (2009) Estrogen and mechanisms of vascular protection. Arterioscler. Thromb. Vasc. Biol., 29: 289–295.
• 14. Tetel M.J., Pfaff D.W. (2010) Contributions of estrogen receptor-α and estrogen receptor-β to the regulation of behavior. Biochim. Biophys. Acta, 1800: 1084–1089.
• 15. McEwen B.S., Davis P.G., Parsons B., Pfaff D.W. (1979) The brain as a target for steroid hormone action. Annu. Rev. Neurosci., 2: 65–112.
• 16. Manolagas S.C., O’Brien C.A., Almeida M. (2013) The role of estrogen and androgen receptors in bone health and disease. Nat. Rev. Endocrinol., 9: 699–712.
• 17. Laurent M., Antonio L., Sinnesael M. et al. (2014) Androgens and estrogens in skeletal sexual dimorphism. Asian J. Androl., 16: 213–222.
• 18. Shi L., Feng Y., Lin H. et al. (2014) Role of estrogen in hepatocellular carcinoma: is inflammation the key? J. Transl. Med., 12: 93.
• 19. Jia G., Aroor A.R., Sowers J.R. (2014) Estrogen and mitochondria function in cardiorenal metabolic syndrome. Prog. Mol. Biol. Transl. Sci., 127: 229–249.
• 20. Barros R.P.A., Gustafsson J.A. (2011) Estrogen receptors and the metabolic network. Cell Metab., 14: 289–299.
• 21. Kim J.H., Cho H.T., Kim Y.J. (2014) The role of estrogen in adipose tissue metabolism: insights into glucose homeostasis regulation. Endocr. J., 61: 1055–1067.
• 22. Caiazza F., Ryan E.J., Doherty G. et al. (2015) Estrogen receptors and their implications in colorectal carcinogenesis. Front. Oncol., 5: 19.
• 23. Barzi A., Lenz A.M., Labonte M.J., Lenz H.J. (2013) Molecular pathways: estrogen pathway in colorectal cancer. Clin. Cancer Res., 19: 5842–5848.
• 24. Thornton M.J. (2013) Estrogens and aging skin. Dermatoendocrinology, 5: 264–270.
• 25. Stevenson S., Thornton J. (2007) Effect of estrogens on skin aging and the potential role of SERMs. Clin. Interv. Aging, 2: 283–297.
• 26. Yeh C.R., Da J., Song W. et al. (2014) Estrogen receptors in prostate development and cancer. Am. J. Clin. Exp. Urol., 2: 161–168.
• 27. Nelson A.W., Tilley W.D., Neal D.E., Carroll J.S. (2014) Estrogen receptor beta in prostate cancer: friend or foe? Endocr. Relat. Cancer, 21: T219–T234.
• 28. Chimento A., Sirianni R., Casaburi I., Pezzi V. (2014) GPER signaling in spermatogenesis and testicular tumors. Front. Endocrinol. (Lausanne), 5: 30.
• 29. Royer C., Lucas T.F., Porto C.S. (2012) 17Betaestradiol signaling and regulation of proliferation and apoptosis of rat Sertoli cells. Biol. Reprod., 86: 108.
• 30. Hess R.A., Fernandes S.A., Gomes G.R. et al. (2011) Estrogen and its receptors in efferent ductules and epididymis. J. Androl., 32: 600–613.
• 31. Shayu D., Hardy M.P., Rao A.J. (2007) Delineating the role of estrogen in regulating Perspectives on the Estrogen Receptors 8 epididymal gene expression. Soc. Reprod. Fertil. Suppl., 63: 31–43.
• 32. Kuiper G.G., Enmark E., Pelto-Huikko M. et al. (1996) Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. USA, 93: 5925–5930.
• 33. Levin E.R., Hammes S.R. (2011) Estrogens and progestins. In: Brunton L. et al. (Eds.) Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 12th ed. McGraw Hill Medical, New York, 1163–1194 pp.
• 34. Sonalkar S., Schreiber C.A., Barnhart K.T. (2014) Contraception. In: De Groot L.J. et al. (Eds.) Endotext. MDText.com, Inc., South Dartmouth, MA.
• 35. Ciruelos E., Pascual T., Vozmediano M.L. et al. (2014) The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer. Breast, 23: 201–208.
• 36. Riggs L., Hartmann L.C. (2003) Selective estrogen-receptor modulators — mechanisms of action and application to clinical practice. N. Engl. J. Med., 348: 618–629.
• 37. Grant M.D., Marbella A., Wang A.T. et al. (2015) Menopausal symptoms: comparative effectiveness of therapies. AHRQ Comparative Effectiveness Rev Mar. Report No. 15-EHC005-EF.
• 38. Gambrel R.D.Jr., Bagnell C.A., Greenblatt R.B. (1983) Role of estrogens and progesterone in the etiology and prevention of endometrial cancer: review. Am. J. Obstet. Gynecol., 146: 696–707.
• 39. Bassuk S.S., Manson J.E. (2015) Oral contraceptives and menopausal hormone therapy: relative and attributable risks of cardiovascular disease, cancer, and other health outcomes. Ann. Epidemiol., 25: 193–200.
• 40. Marshall A.L. (2014) Diagnosis, treatment, and prevention of venous thromboembolism in pregnancy. Postgrad. Med., 126: 25–34.
• 41. Aranda A., Pascual A. (2001) Nuclear hormone receptors and gene expression. Physiol. Rev., 81: 1269–1304.
• 42. Shang Y., Hu X., DiRenzo J. et al. (2000) Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell, 103: 843–852.
• 43. DiRenzo J., Shang Y., Phelan M. et al. (2000) BRG-1 is recruited to estrogen-responsive promoters and cooperates with factors involved in histone acetylation. Mol. Cell Biol., 20: 7541–7549.
• 44. Stashi E., York B., O’Malley B.W. (2014) Steroid receptor coactivators: servants and masters for control of systems metabolism. Trends Endocrinol. Metab., 25: 337–347.
• 45. Lannigan D.A. (2003) Estrogen receptor phosphorylation. Steroids, 68: 1–9.
• 46. Carroll J.S., Brown M. (2006) Estrogen receptor target gene: an evolving concept. Mol. Endocrinol., 20: 1707–1714.
• 47. Carroll J.S., Meyer C.A., Song J. et al. (2006) Genome-wide analysis of estrogen receptor binding sites. Nat. Genet., 38: 1289–1297.
• 48. Bourdeau V., Deschênes J., Métivier R. et al. (2004) Genome-wide identification of Perspectives on the Estrogen Receptors 10 high- affi nity estrogen response elements in human and mouse. Mol. Endocrinol., 18: 1411–1427.
• 49. Safe S., Kim K. (2008) Non-classical genomic estrogen receptor (ER)/specificity protein and ER/activating protein-1 signaling pathways. J. Mol. Endocrinol., 41: 263–275.
• 50. Safe S. (2001) Transcriptional activation of genes by 17 beta-estradiol through estrogen receptor-Sp1 interactions. Vitam. Horm., 62: 231–252.
• 51. Paech K., Webb P., Kuiper G.G. et al. (1997) Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science, 277: 1508–1510.
• 52. Jakacka M., Ito M., Weiss J. et al. (2001) Estrogen receptor binding to DNA is not required for its activity through the nonclassical AP1 pathway. J. Biol. Chem., 276: 13615–13621.
• 53. Biswas D.K., Singh S., Shi Q. et al. (2005) Crossroads of estrogen receptor and NF-kappaB signaling. Sci. STKE, 2005(288): pe27.
• 54. Dubey R.K., Jackson E.K. (2009) Potential vascular actions of 2-methoxyestradiol. Trends Endocrinol. Metab., 20: 374–379.
• 55. Dubey R.K., Tofovic S.P., Jackson E.K. (2004) Cardiovascular pharmacology of estradiol metabolites. J. Pharmacol. Exp. Ther., 308: 403–409.
• 56. Ruan X., Seeger H., Wallwiener D. et al. (2015) The ratio of the estradiol metabolites 2-hydroxyestrone (2-OHE1) and 16α-hydroxyestrone (16-OHE1) may predict breast cancer risk in postmenopausal but not in premenopausal women: two case-control studies. Arch. Gynecol. Obstet., 291: 1141–1146.
• 57. Umetani M., Shaul P.W. (2011) 27-Hydroxycholesterol: the first identified endogenous SERM. Trends Endocrinol. Metab., 22: 130–135.
• 58. Nelson E.R., Wardell S.E., McDonnell D.P. (2013) The molecular mechanisms underlying the pharmacological actions of estrogens, SERMs and oxysterols: implications for the treatment and prevention of osteoporosis. Bone, 53: 42–50.
• 59. Setchell K.D.R. (1998) Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones. Am. J. Clin. Nutr., 68(Suppl.): 1333S–1346S.
• 60. Brzezinski A., Debi A. (1999) Phytoestrogens: the «natural» selective estrogen receptor modulators? Eur. J. Obstet. Gynecol. Reprod. Biol., 85: 47–51.
• 61. Muthyala R.S., Ju Y.H., Sheng S. et al. (2004) Equol, a natural estrogenic metabolite from soy isoflavones: convenient preparation and resolution of R- and S-equols and their differing binding and biological activity through estrogen receptors alpha and beta. Bioorg. Med. Chem., 12: 1559–1567.
• 62. Jackson R.L., Greiwe J.S., Schwen R.J. (2011) Emerging evidence of the health benefits of S-equol, an estrogen receptor β agonist. Nutr. Rev., 69: 432–448.
• 63. The North American Menopause Society (2010) Menopause practice: A clinician’s guide. 4th edition. Mayfield Heights, OH: NAMS.
• 64. McCall-Hosenfeld J.S., Jaramillo S.A., Legault C. et al. (2008) Correlates of sexual satisfaction among sexually active postmenopausal women in the Women’s Health Initiative Observational Study. J. Gen. Intern. Med., 23: 2000–2009.
• 65. Schneidewind-Skibbe A., Hayes R.D., Koochaki P.E. et al. (2008) The frequency of sexual intercourse reported by women: A review of community-based studies and factors limiting their conclusions. J. Sex. Med., 5: 301–335.
• 66. Tan O., Bradshaw K., Carr B.R.(2012) Management of vulvovaginal atrophy-related sexual dysfunction in postmenopausal women: An up-to-date review. Menopause, 19: 109–117.
• 67. Nappi R.E., Palacios S. (2014) Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric, 17: 3–9.
• 68. MacBride M.B., Rhodes D.J., Shuster L.T. (2010) Vulvovaginal atrophy. Mayo Clin. Proc., 85: 87–94.
• 69. Kingsberg S., Kellogg S., Krychman M. (2009) Treating dyspareunia caused by vaginal atrophy: A review of treatment options using vaginal estrogen therapy. Int. J. Womens Health, 1: 105–111.
• 70. Brotman R.M., Shardell M.D., Gajer P. et al. (2014) Association between the vaginal microbiota, menopause status, and signs of vulvovaginal atrophy. Menopause, 21: 450–458.
• 71. Muhleisen A.L., Herbst-Kralovetz M.M. (2016) Menopause and the vaginal microbiome. Maturitas, 91: 42.
• 72. Berman J.R., Almeida F.G., Jolin J. et al. (2003) Correlation of androgen receptors, aromatase, and 5-alpha reductase in the human vagina with menopausal status. Fertil. Steril., 79: 925.
• 73. Baldassarre M., Perrone A.M., Giannone F.A. et al. (2013) Androgen receptor expression in the human vagina under different physiological and treatment conditions. Int. J. Impot. Res., 25: 7.
• 74. Melisko M.E., Goldman M.E., Hwang J. et al. (2017) Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial. JAMA Oncol., 3: 313.
• 75. Hummelen R., Macklaim J.M., Bisanz J.E. et al. (2011) Vaginal microbiome and epithelial gene array in post-menopausal women with moderate to severe dryness. PLoS ONE, 6: e26602.
• 76. Santen R.J., Mirkin S., Bernick B., Constantine G.D. (2020) Systemic estradiol levels with low-dose vaginal estrogens. Menopause, 27: 361.
• 77. Rueda C., Osorio A.M., Avellaneda A.C. et al. (2017) The efficacy and safety of estriol to treat vulvovaginal atrophy in postmenopausal women: a systematic literature review. Climacteric, 20: 321.
• 78. Simon J., Nachtigall L., Ulrich L.G. et al. (2010) Endometrial safety of ultra-low-dose estradiol vaginal tablets. Obstet. Gynecol., 116: 876.
• 79. Barnabei V.M., Cochrane B.B., Aragaki A.K. et al. (2005) Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women’s Health Initiative. Obstet. Gynecol., 105: 1063.
• 80. Simunić V., Banović I., Ciglar S. et al. (2003) Local estrogen treatment in patients with urogenital symptoms. Int. J. Gynaecol. Obstet., 82: 187.
• 81. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause 2017.
• 82. Long C.Y., Liu C.M., Hsu S.C. et al. (2006) A randomized comparative study of the effects of oral and topical estrogen therapy on the vaginal vascularization and sexual function in hysterectomized postmenopausal women. Menopause, 13: 737.
• 83. Costantino D., Guaraldi C. (2008) Effectiveness and safety of vaginal suppositories for the treatment of the vaginal atrophy in postmenopausal women: an open, non-controlled clinical trial. Eur. Rev. Med. Pharmacol. Sci., 12: 411.
• 84. Cardozo L., Bachmann G., McClish D. et al. (1998) Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet. Gynecol., 92: 722.
• 85. Barlow D.H., Cardozo L.D., Francis R.M. et al. (1997) Urogenital ageing and its effect on sexual health in older British women. Br. J. Obstet. Gynaecol., 104: 87.
• 86. Rossouw J., Anderson G., Prentice R. et al. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA, 288: 321–333.
• 87. https://www.drugs.com/newdrugs/fda-approves-osphena-postmenopausal-women-experiencing-dyspareunia-3706.html
• 88. Bachmann G.A., Komi J.O., Ospemifene Study Group (2010) Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause, 17: 480.
• 89. Portman D.J., Bachmann G.A., Simon J.A., Ospemifene Study Group (2013) Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause, 20: 623.
• 90. Constantine G., Graham S., Portman D.J. et al. (2015) Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial. Climacteric, 18: 226.
• 91. Goldstein I., Simon J.A., Kaunitz A.M. et al. (2019) Effects of ospemifene on genitourinary health assessed by prospective vulvar-vestibular photography and vaginal/vulvar health indices. Menopause, 26: 994.
• 92. Rutanen E.M., Heikkinen J., Halonen K. et al. (2003) Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial. Menopause, 10: 433.
• 93. Simon J.A., Lin V.H., Radovich C. et al. (2013) One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause, 20: 418.
• 94. Goldstein S., Bachmann G., Lin V. et al. (2011) Endometrial safety profile of ospemifene 60 mg when used for long-term treatment of vulvar and vaginal atrophy for up to 1 year. Climacteric, 14: S57.
• 95. Wurz G.T., Soe L.H., DeGregorio M.W. (2013) Ospemifene, vulvovaginal atrophy, and breast cancer. Maturitas, 74: 220.
• 96. Burich R.A., Mehta N.R., Wurz G.T. et al. (2012) Ospemifene and 4-hydroxyospemifene effectively prevent and treat breast cancer in the MTag.Tg transgenic mouse model. Menopause, 19: 96.